Gluvan 50 mg (Tablet)
Unit Price: ৳ 20.00 (2 x 14: ৳ 560.00)
Strip Price: ৳ 280.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Vildagliptin |
| Company | Aristopharma ltd |
Indications
- Adjunct to diet and exercise
- Improves glycemic control
- Type 2 diabetes mellitus
- Monotherapy
- Dual combination therapy
- With Metformin
- With Sulphonylurea
- With Thiazolidinedione
- With Insulin
- Inadequate glycemic control
Pharmacology
- Dipeptidyl peptidase-4 (DPP-4) inhibitor
- Slows inactivation of incretin hormones
- Regulates glucose homeostasis
- Increases insulin release
- Decreases glucagon levels
- Glucagon-like peptide-1 (GLP-1)
- Glucose-dependent insulinotropic polypeptide (GIP)
- Endogenous system
Dosage & Administration
- 50 mg daily for monotherapy
- 100 mg daily for monotherapy
- 50 mg twice daily in combination with Metformin
- 50 mg once daily in combination with Sulphonylurea
- May be taken with or without a meal
- No dosage adjustment for elderly
- No dosage adjustment for mild renal impairment
- Not recommended for pediatric use
Interaction
- No interactions with pioglitazone
- No interactions with metformin
- No interactions with glibenclamide
- No interactions with digoxin
- May be reduced by thiazides
- May be reduced by corticosteroids
- May be reduced by thyroid products
- May be reduced by sympathomimetics
Contraindications
- Hypersensitivity to active substance or excipients
- Moderate to severe renal impairment
- Pre-treatment alanine aminotransferase (ALT) >3 times ULN
- Pre-treatment aspartate aminotransferase (AST) >3 times ULN
- Type 1 diabetes
Side Effects
- Majority of adverse reactions are mild and transient
- Rare case of hepatic dysfunction
- No additional safety signals in long-term trials
Pregnancy & Lactation
- Not to be used in pregnancy
- Not to be used during lactation
Precautions & Warnings
- Caution in patients aged 75 years and older
- Limited clinical experience in patients aged 75 years and older
- Liver function tests (LFTs) monitoring
- Increased transaminase levels monitoring
- Jaundice or other signs of liver dysfunction monitoring
- Discontinue treatment for increased transaminase levels
- Discontinue treatment for jaundice or signs of liver dysfunction
- No reinitiation of treatment after withdrawal and LFT normalization
- Caution in patients with congestive heart failure
- Do not use in patients with NYHA functional class III IV
Therapeutic Class
- Dipeptidyl Peptidase-4 (DPP-4) inhibitor
Storage Conditions
- Store below 30°C
- Keep away from light
- Keep away from moisture
- Keep out of reach of children